Beijing Tiantan Biological Products Corporation (600161.SH) announced that its subsidiary Chengdu Rongsing Pharmaceutical Co., Ltd. (abbreviated as "Cheng...")
According to the Zhitong Finance APP, Beijing Tiantan Biological Products Corporation (600161.SH) announced that its subsidiary Chengdu Rongsong Pharmaceutical Co., Ltd. (referred to as "Chengdu Rongsong") has completed the phase III clinical trial of "Recombinant Human Coagulation Factor VIIa for Injection" and obtained the clinical trial summary report. The phase III clinical study results showed that the recombinant human coagulation factor VIIa produced by Chengdu Rongsong effectively improved the bleeding symptoms and signs in adult and adolescent (≥12 years) patients with hemophilia A/B with inhibitors after infusion, demonstrating good efficacy. In terms of safety, the incidence of adverse reactions for the product is low, and most common types of adverse reactions are consistent with the clinical trial data published in the instructions of similar foreign products.
